Russ Altman writes that with all the competition in the genome sequencing space, particularly with Complete Genomics' recent announcement, researchers be able to get their "entire genome sequence basically for free." He says this will have an impact on medicine, particularly pharmacogenomics and predictive diagnostics. Altman also worries that the current methods of trying to protect consumers by relying on government regulations or requiring a physician will not work. "We must work to educate every day people about how to interpret their genome and how to use the information beneficially," Altman writes.
Premium Trial: